Bowel Mass
A bowel mass is a growth or lesion within or arising from the wall of the small or large intestine. Bowel masses can result from a wide range of conditions—including cancers (adenocarcinoma, lymphoma, carcinoid/neuroendocrine tumors, gastrointestinal stromal tumors, and metastases), benign tumors and polyps, inflammatory conditions, and, less commonly, other processes. Because the possible diagnoses have very different treatments and prognoses, careful evaluation is important. Most bowel masses require tissue diagnosis, typically obtained through endoscopy with biopsy, for accurate identification and treatment planning. Evaluation combines imaging (particularly CT), endoscopy (colonoscopy, upper endoscopy, or specialized small bowel techniques), and biopsy.
What is it?
The bowel (intestine) is divided into the small intestine (which includes the duodenum, jejunum, and ileum) and the large intestine (which includes the cecum, colon, and rectum). The bowel wall has several layers, including the inner mucosa (which lines the lumen and produces mucus and other secretions), the submucosa (a connective tissue layer with blood vessels, nerves, and lymphatics), the muscularis propria (the muscle layer that produces the contractions that move food through the bowel), and the outer serosa (in most parts of the bowel). Growths and lesions can arise from any of these layers and produce what is broadly described as a “bowel mass” on imaging or at endoscopy.
Bowel masses can be classified by their origin and behavior.
Benign growths include:
– Polyps of various types (particularly adenomatous polyps and hyperplastic polyps in the colon and rectum, and other types), which are extremely common in adults
– Lipomas (fatty tumors) — benign growths of fat tissue that can occur in any part of the bowel
– Leiomyomas — benign smooth muscle tumors
– Fibromas and other benign connective tissue tumors
– Neurogenic tumors (such as schwannomas)
– Inflammatory pseudopolyps (in inflammatory bowel disease)
Cancers include:
– Adenocarcinoma — the most common bowel cancer overall, arising from the glandular cells of the lining; most colorectal cancers are adenocarcinomas, and adenocarcinoma is also the most common small bowel cancer, though bowel cancer is much less common in the small intestine
– Neuroendocrine tumors (carcinoids) — tumors arising from hormone-producing cells; most common in the small bowel (particularly the ileum) and appendix, but can occur elsewhere
– Lymphoma — cancer of lymphoid cells; the gastrointestinal tract is the most common site of extranodal lymphoma
– Gastrointestinal stromal tumors (GISTs) — tumors arising from the interstitial cells of Cajal in the bowel wall, can occur throughout the gastrointestinal tract but are less common in the bowel than the stomach
– Squamous cell carcinoma — uncommon in most bowel locations but can occur in the anal canal
– Metastases from cancers elsewhere — including from lung, breast, melanoma, ovary, and other primary cancers
Inflammatory or infectious lesions include:
– Inflammatory bowel disease—related lesions (mass-like inflammatory changes in Crohn’s disease or ulcerative colitis)
– Tuberculous and other infectious granulomatous lesions
– Endometriosis affecting the bowel (typically in reproductive-age women)
– Abscesses (localized infections)
Other conditions include intussusception (telescoping of one bowel segment into another, which can appear as a mass), volvulus (twisting), and, less commonly, other structural conditions.
The evaluation approach for a suspected or identified bowel mass depends on the specific location, presentation, and clinical context.
For colon and rectal masses, colonoscopy is generally the primary evaluation tool. It allows direct visualization of the mass, characterization of its appearance, and biopsy for tissue diagnosis. Many small polyps can be removed entirely at the time of colonoscopy (polypectomy), providing both diagnosis and treatment for benign or precancerous lesions.
For small bowel masses, the mid and distal small bowel are difficult to access with standard endoscopy, and specialized techniques may be needed. These include capsule endoscopy (in which the patient swallows a small camera that images the bowel as it passes through), deep enteroscopy (with balloon-assisted techniques that allow the endoscope to reach farther into the small bowel), and specialized imaging (CT enterography or MR enterography, which are dedicated protocols for detailed small bowel evaluation). Occasionally, evaluation may require surgical exploration.
For stomach and duodenal masses (which may be described as bowel masses when the small bowel is involved), upper endoscopy is the primary evaluation tool and allows visualization and biopsy.
CT of the abdomen and pelvis, typically with intravenous and oral contrast, is often obtained early in the evaluation of a suspected bowel mass. It provides comprehensive evaluation of the bowel wall, mesentery, lymph nodes, blood supply, and other organs, and can identify features that suggest specific diagnoses. Certain findings can favor particular diagnoses—for example, marked bowel wall thickening with an open lumen (aneurysmal dilation) and prominent lymphadenopathy may suggest lymphoma; a stricturing mass with proximal bowel dilation may suggest adenocarcinoma; and specific patterns may suggest inflammatory conditions.
MRI is particularly useful for detailed evaluation of rectal masses (for staging of rectal cancer) and for specific small bowel evaluations. PET/CT is used in specific settings, particularly for lymphoma staging and for some other cancer evaluations.
Biopsy is essential for definitive diagnosis. Endoscopic biopsy is preferred when the mass is accessible. Image-guided biopsy or surgical biopsy may be needed for masses that cannot be reached endoscopically. Adequate tissue is important, particularly for accurate lymphoma diagnosis and subtyping, and, in some cases, core needle biopsy or surgical biopsy is preferred over fine-needle aspiration alone.
Blood tests including complete blood count (which may show anemia from slow blood loss), kidney and liver function, tumor markers such as CEA (carcinoembryonic antigen) when colorectal cancer is suspected, and, in specific cases, other markers, are often obtained.
For patients with suspected hereditary syndromes (based on young age at diagnosis, family history, multiple primary cancers, or specific tumor features), evaluation may include genetic counseling and testing.
Important to Know
Management of a bowel mass depends entirely on the specific diagnosis, and the approach differs substantially between benign and malignant conditions and between different cancer types. Care is typically coordinated by primary care clinicians (for initial evaluation), gastroenterologists (for endoscopic evaluation and, in some cases, treatment), colorectal or general surgeons, medical oncologists (for cancer treatment), radiation oncologists (particularly for rectal cancer), radiologists, and, when needed, other specialists including hematology-oncology for lymphoma, hepatobiliary surgery for certain small bowel or duodenal tumors, and genetics for hereditary conditions.
For benign polyps identified on colonoscopy, treatment is often accomplished at the time of the procedure. Small polyps can typically be removed entirely with a snare or forceps (polypectomy). Larger polyps or those in specific locations may require more advanced techniques such as endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD), which allow removal of larger lesions while preserving the bowel wall. Following polyp removal, follow-up colonoscopy at intervals determined by the specific polyp characteristics and other factors is important for continued surveillance.
For adenocarcinoma of the bowel, treatment depends on the location and stage. Surgical resection of the affected bowel segment along with associated lymph nodes is typically the mainstay of curative treatment. Chemotherapy may be added before surgery (neoadjuvant), after surgery (adjuvant), or as primary treatment in advanced disease. For rectal cancer, treatment often involves a multimodal approach with chemotherapy, radiation, and surgery. Immunotherapy has an important role in tumors with mismatch repair deficiency or high microsatellite instability. Targeted therapies are used based on specific molecular characteristics.
For neuroendocrine tumors (carcinoids), treatment depends on the specific location, size, grade, and extent. Surgery is typically the mainstay for localized disease, with additional treatments (somatostatin analogues, peptide receptor radionuclide therapy, targeted therapies, and others) for advanced disease.
For lymphoma involving the bowel, treatment is directed by the specific lymphoma subtype and typically involves chemoimmunotherapy rather than primary surgical treatment. Surgery is generally reserved for complications such as perforation, obstruction, or significant bleeding.
For gastrointestinal stromal tumors (GISTs), treatment includes surgical resection for localized disease and targeted therapy with tyrosine kinase inhibitors (particularly imatinib and other agents) for tumors with certain characteristics or in advanced disease.
For metastases from cancers elsewhere, treatment focuses on the primary cancer, and management is guided by cancer-specific principles.
For inflammatory bowel disease—related mass-like lesions, treatment focuses on management of the underlying inflammatory bowel disease with medications, and, in some cases, endoscopic or surgical treatment. Distinguishing inflammatory pseudopolyps from true polyps or cancer can sometimes require careful evaluation.
For endometriosis of the bowel, treatment options include hormonal therapy and, in specific cases, surgical resection.
For patients presenting acutely with complications such as bowel obstruction, perforation, or significant bleeding, urgent evaluation and, in many cases, urgent intervention are needed. Emergency surgery may be required in specific circumstances, and the underlying diagnosis often becomes clearer after acute stabilization.
Screening and surveillance play important roles. For patients meeting criteria for colorectal cancer screening (which now typically begins at age 45 for average-risk adults in the United States, with earlier and more frequent screening for those with risk factors), regular colonoscopy or other approved screening tests can identify and remove precancerous polyps and detect cancers at early stages. For patients with a history of polyps or cancer, ongoing surveillance is important.
For patients with hereditary syndromes (such as Lynch syndrome, FAP, and others), specialized surveillance protocols and preventive strategies are important.
Nutritional support, physical rehabilitation (particularly after major surgery), mental health support, and support for family and caregivers are important components of comprehensive care.
For patients with advanced or metastatic disease, palliative care can be integrated alongside cancer-directed treatment at any stage.
Care during pregnancy in patients with a bowel mass requires special attention, and management is highly individualized based on the specific diagnosis, gestational age, and other factors. Coordination with obstetrics, maternal-fetal medicine, and relevant specialties is essential.
Care is typically coordinated by the appropriate specialists depending on the specific diagnosis. Imaging, laboratory, pathology, and molecular findings are interpreted alongside the patient’s symptoms, examination, family history, and broader clinical context rather than in isolation.
Patient education plays an essential role. Understanding the diagnosis, the specific characteristics of the mass, the rationale for the recommended treatment plan, the meaning of imaging and laboratory findings, treatment side effects, the importance of any recommended surveillance, and warning signs of complications all contribute to better outcomes. Given the wide range of possible diagnoses, clear communication about the specific condition and expected next steps is particularly important.
Red flag symptoms include severe abdominal pain, symptoms of bowel obstruction (severe abdominal pain, distention, vomiting, inability to pass stool or gas), significant gastrointestinal bleeding (large amounts of visible blood, black tarry stools, or lightheadedness with bleeding), high fever with signs of severe infection, sudden severe pain (which may suggest perforation), signs of sepsis, severe difficulty breathing, new severe back pain with weakness, numbness, or bowel or bladder changes, unintended significant weight loss, jaundice, or rapid clinical deterioration. These warrant prompt or urgent medical evaluation.